Put Options

17 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$7.45 - $13.84 $82,695 - $153,624
11,100 New
11,100 $107,000
Q1 2022

May 16, 2022

SELL
$9.94 - $12.65 $170,968 - $217,580
-17,200 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$11.99 - $18.14 $206,228 - $312,008
17,200 New
17,200 $212,000
Q3 2021

Nov 12, 2021

SELL
$11.55 - $16.06 $331,485 - $460,921
-28,700 Closed
0 $0
Q2 2021

Aug 06, 2021

BUY
$12.38 - $29.19 $96,564 - $227,682
7,800 Added 37.32%
28,700 $414,000
Q1 2021

May 14, 2021

BUY
$15.07 - $21.71 $3,014 - $4,342
200 Added 0.97%
20,900 $430,000
Q4 2020

Feb 12, 2021

SELL
$12.72 - $16.16 $12,720 - $16,160
-1,000 Reduced 4.61%
20,700 $318,000
Q3 2020

Nov 13, 2020

SELL
$12.34 - $17.92 $303,564 - $440,832
-24,600 Reduced 53.13%
21,700 $268,000
Q2 2020

Aug 13, 2020

BUY
$12.39 - $17.33 $39,648 - $55,455
3,200 Added 7.42%
46,300 $777,000
Q1 2020

May 11, 2020

BUY
$9.12 - $17.78 $22,799 - $44,450
2,500 Added 6.16%
43,100 $572,000
Q4 2019

Feb 12, 2020

SELL
$16.11 - $25.98 $336,699 - $542,982
-20,900 Reduced 33.98%
40,600 $666,000
Q3 2019

Nov 14, 2019

SELL
$18.28 - $26.91 $38,388 - $56,511
-2,100 Reduced 3.3%
61,500 $1.15 Million
Q2 2019

Aug 20, 2019

SELL
$17.68 - $21.57 $523,328 - $638,472
-29,600 Reduced 31.76%
63,600 $1.37 Million
Q1 2019

May 15, 2019

BUY
$14.41 - $19.64 $596,574 - $813,096
41,400 Added 79.92%
93,200 $1.83 Million
Q4 2018

Feb 14, 2019

BUY
$12.45 - $23.47 $97,110 - $183,066
7,800 Added 17.73%
51,800 $658,000
Q3 2018

Nov 14, 2018

BUY
$17.57 - $23.95 $272,335 - $371,225
15,500 Added 54.39%
44,000 $1.05 Million
Q1 2018

May 15, 2018

BUY
$11.77 - $16.08 $335,445 - $458,279
28,500 New
28,500 $353,000

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $260M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.